Trial-Results center  
Clinical trial results database in 100 Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

heart failure - angiotensin-Converting Enzyme Inhibitors - all type of heart failure


Related trials

PEP CHF, 2006 - perindopril vs placebo

ATLAS, 1999 - lisinopril vs lisinopril

Hampton, 1998 - trandolapril vs placebo

NETWORK (2.5 bid vs 10 bid), 1998 - enalapril vs enalapril

NETWORK (5 bid vs 10 bid), 1998 - enalapril vs enalapril

FEST (Erhardt), 1996 - fosinopril vs placebo

Cilazapril-Captopril Multi-centre Group (capt vs pbo), 1995 - captopril vs placebo

CASSIS (enalapril), 1995 - enalapril vs placebo

Cilazapril-Captopril Multi-centre Group, 1995 - cilazapril vs placebo

Cilazapril-Captopril Multi-centre Group (cila vs capt), 1995 - cilazapril vs captopril

Brown, 1995 - fosinopril vs placebo

CASSIS (spirapril), 1995 - spirapril vs placebo

Gundersen, 1994 - ramipril vs placebo

Uprichard-c, 1994 - vs control

Uprichard-b, 1994 - vs control

Uprichard-a, 1994 - vs control

Nussberger, 1994 - vs placebo

Dosseger, 1993 - cilazapril vs placebo

Quinapril Heart Failure Trial Investigators, 1993 - vs placebo

Lechat, 1993 - perindopril vs placebo

Gilbert, 1993 - lisinopril vs placebo

SOLVD prevention, 1992 - enalapril vs placebo

Munich MHFT (Kleber), 1992 - captopril vs placebo

Lemarie, 1992 - ramipril vs placebo

Colfer, 1992 - benazepril vs placebo



See also:

  • All heart failure clinical trials
  • All clinical trials of angiotensin-Converting Enzyme Inhibitors
  • All clinical trials of enalapril
  •  

    SOLVD prevention study, 1992

    [NCT00000516] download pdf: enalapril | angiotensin-Converting Enzyme Inhibitors for heart failure

    Treatments

    Studied treatment Enalapril initial dose 2·5 or 5 mg twice daily up to 10 mg twice daily
    Control treatment placebo

    Patients

    Patients MI >1 month,No treatment for CHF, LVEF <=35%
    Inclusion criteria EF <=0.35 (istotope, echo or cathetism) without clinical signs of congestive heart failure
    Baseline characteristics
    Ischemic origin 83% 
    Stade NYHA I-II 
    Female (%) 11% 
    Age 59 y 

    Method and design

    Randomized effectives 2111 / 2117 (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 3.1 y
    Lost to follow-up 0.2%
    Hypothesis Superiority
    Withdrawals (T1/T0) 3.1 y /


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    All cause death

    313 / 2111
    334 / 2117
    0,94 [0,82;1,08]

    hospitalisation for heart failure

    306 / 2111
    454 / 2117
    0,68 [0,59;0,77]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    All cause death 313 / 2111 (14,8%) 334 / 2117 (15,8%) 0,94 [0,82;1,08]   0
    hospitalisation for heart failure 306 / 2111 (14,5%) 454 / 2117 (21,4%) 0,68 [0,59;0,77]  
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 14,83% 15,78% -9,5‰
    hospitalisation for heart failure 14,50% 21,45% -69,5‰

    Meta-analysis of all similar trials:

    angiotensin-Converting Enzyme Inhibitors in heart failure for all type of heart failure



    Reference(s)

    Trials register # NCT00000516
    • . Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992;327:685-91
      Pubmed | Hubmed | Fulltext

    (c) 2004-2014 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100100